54 results about "Meticillin" patented technology

The invention belongs to the technical field of biomedicine and nano material electronics, and particularly relates to a low-voltage efficient sterilization electrode device based on local enhanced electric field treatment. According to the electrode device, vertically-oriented nanoneedles serve as a core functional layer, a nanoneedle array is arranged on a conductive substrate, the intensity of an electric field in a pinpoint area is amplified by multiple times through the lightning rod effect induced by the tips of the nanoneedles so as to achieve irreversible electroporation of a low-potential induced pathogen membrane, the length of the nanoneedles is 5-100 micrometers, and the length of the nanoneedles is 5-100 micrometers. The curvature radius of the needle tip is lt; and the sterilization device can realize nearly complete sterilization on escherichia coli and methicillin-resistant staphylococcus aureus within 5 minutes. The invention further provides a nanometer microneedle sterilization patch based on the local enhanced electric field, a self-power-supply or external-source-power-supply energy supply mode is adopted, and rapid sterilization of a wound can be achieved without medicine adding.

This invention relates to a 1,3,4-thiadiazole peptide deformylase inhibitor and its preparation and application. The structural formula is shown in formula (1): wherein, R 1 It is n-butyl or cyclopentylmethyl; R 2 The compounds are hydrogen-containing, straight-chain alkanes, cyclic alkanes, aromatic rings, substituted biphenyls, or heterocyclic rings. The 1,3,4-thiadiazole peptide deformylase inhibitors provided by this invention can effectively inhibit bacterial protein synthesis, thereby achieving sterilization. These compounds exhibit excellent inhibitory activity against Gram-positive drug-resistant bacteria, especially the clinically challenging methicillin-resistant Staphylococcus aureus (MRSA). In particular, some preferred compounds show inhibitory activity 4-8 times that of the control standards vancomycin and linezolid. The 1,3,4-thiadiazole peptide deformylase inhibitors provided by this invention also exhibit inhibitory activity against Gram-negative drug-resistant bacteria, especially against drug-resistant Acinetobacter baumannii, known as "superbugs," with an inhibitory activity reaching 0.5 μg / mL, far superior to vancomycin and linezolid.

The invention relates to application of golden larch bark acetic acid in preparation of methicillin-resistant staphylococcus aureus (MRSA) biological membrane and bacterium holding inhibitor. A biological membrane formation inhibition experiment shows that the pseudolaric acid can remarkably inhibit formation of an MRSA biological membrane, a fluorescent quantitative PCR experiment shows that the pseudolaric acid remarkably reduces transcription of related genes of the MRSA biological membrane, and a persistent bacterium killing experiment shows that the pseudolaric acid enhances the killing capability of gentamicin on MRSA persistent bacteria. Lung epithelial cell adhesion tests find that the golden larch bark acetic acid significantly reduces the adhesion effect of the MRSA strain on epithelial cells. A test for constructing an MRSA infected greater wax moth model shows that the golden larch bark acetic acid has a system protection effect on the MRSA infected greater wax moth model.

The invention relates to the field of modern pharmacy of traditional Chinese medicines, and discloses application of leonurine in preparation of antibacterial products. According to the invention, the in-vitro antibacterial activity of leonurine is detected by an agar dilution method and a broth trace dilution method. The result shows that the leonurine can inhibit the proliferation of a staphylococcus aureus standard strain, and also has an inhibiting effect on most of methicillin-sensitive staphylococcus aureus, methicillin-resistant staphylococcus aureus and methicillin-resistant coagulase-negative staphylococcus which are obtained by clinical separation; meanwhile, the leonurine can inhibit proliferation of a malassezia standard strain and a clinical isolated strain, also has an inhibiting effect on most of ketoconazole drug-resistant candida and ketoconazole dose dependence-sensitive candida obtained through clinical isolation, and can be used for preparing antibacterial pharmaceutical compositions and skin care products.

Described herein is a synergistic combination comprising a quorum-sensing inhibitor and / or postbiotic metabolite and an antibiotic. Typically, the postbiotic metabolite comprises at least one peptide. Related compositions, uses, and methods are also described, including methods for resensitizing resistant bacteria to an antibiotic, and methods of treating antibiotic-resistant infections, such as methicillin-resistant Staphylococcus aureus (MRSA).

The invention discloses a manganese-based layered hydroxide modified by gold nanoparticles and a preparation method thereof, and relates to the technical field of drug synthesis, and the key points of the technical scheme are as follows: the layered morphology of Mn-LDH is observed on the manganese-based layered hydroxide in a transmission electron microscope, and spherical AuNPs dispersed on the surface and edge of a laminate have a uniform particle size and a uniform particle size. EDS energy spectrum analysis finds that gold, manganese, magnesium, aluminum and carbon elements exist, the hydrated particle size is 312 nm, and the dispersity is good. The material can initiate an excellent photo-thermal effect under the irradiation of 808nm near-infrared light to generate active oxygen and hydroxyl radicals to destroy bacterial cell walls and cell membranes, and the antibacterial effect can reach 99%. In addition, the material can stimulate a local active immune function, promote T cell infiltration and realize active immune sterilization. The nano material shows a remarkable anti-infection effect in an in-vitro antibacterial experiment and an in-vivo osteomyelitis animal model experiment, and a new insight is provided for treating osteomyelitis caused by methicillin-resistant staphylococcus aureus.

Naphthoquinone derivatives of Lawsone have been found to be effective against Staphylococcus aureus and methicillin resistant Staphylococcus aureus (MRSA). Such compounds generally contain a substituent group at the 3-position of a specific naphthoquinone compound, i.e. 2-hydroxy-1,4-naphthoquinone. One of these derivatives referred to as compound 6c in the series exhibits potent antimicrobial activity that is comparable to that of the two commercial antibiotics ofloxacin and ciprofloxacin against the two strains of methicillin sensitive Staphylococcus aureus (MSSA; ATCC 29213 and ATCC 6538). In the case of two strains of MRSA (ATCC BAA-44 and ATCC BAA-1717) that have developed drug resistance to both ofloxacin and ciprofloxacin, the antimicrobial activity of 6c can almost rival that of vancomycin and daptomycin. Furthermore, 6c is also effective against vancomycin-intermediate and daptomycin non-susceptible strain of MRSA (ATCC 700699). Besides the efficacy, 6c has a much improved drug resistance profile in comparison with the conventional antibiotics.

Lipid-based drug delivery vehicles (including liposomal nanoparticles) are described which include antibiotic(s) for the treatment of infections, such as Methicillin-Resistant Staphylococcus (S.) aureus (MRSA) infections and Methicillin-Susceptible S. aureus (MSSA) infections. These drug delivery vehicles have high drug-loading, do not accumulate in the liver, and can optionally include one or more targeting ligands.

The invention provides an application of SX-682 in preparation of a drug for resisting staphylococcus aureus infection, and the SX-682 has a CAS number of 1648843-04-2. According to the technical scheme, the novel medical application of the SX-682 is disclosed, and the SX-682 has better antibacterial activity on staphylococcus aureus and can inhibit formation of biofilms including methicillin-sensitive staphylococcus aureus (MSSA) and methicillin-resistant staphylococcus aureus (MRSA). The SX-682 has no significant toxicity to human cytotoxicity in the bacteriostatic concentration range, and provides key support for subsequent anti-infection application of the SX-682.

This invention discloses the application of the bacterial fission protein FtsZ inhibitor DB1 in the preparation of drugs against drug-resistant bacteria, belonging to the field of drug development technology. The inhibitor provided by this invention is compound DB1, named 3-(2,8-dibromo-10,11-dihydro-5H-dibenzo[b,f]azapheno-5-yl)-N,N-dimethylpropylamine hydrochloride, with the molecular formula C2. 19 H 24 Br2ClN2. This compound, DB1, exhibits significant inhibitory effects against various drug-resistant bacteria, particularly vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus (MRSA), and can significantly improve the susceptibility of methicillin to MRSA. The discovery of compound DB1 provides new ideas and technical support for the preparation of drugs against drug-resistant bacteria.

The application provides a fusariobutenolide derivative 4''-O-isopentenyl fusariobutenolide C, and a structural formula of the compound is provided.The 4''-O-isopentenyl fusariobutenolide C can significantly inhibit the growth of seven human routine pathogenic bacteria in antibacterial activity testing, and the MIC is 8.6-28.3 μg / mL, and the antibacterial effect on one strain of human drug-resistant pathogenic bacteria, methicillin-resistant Staphylococcus aureus, is significant, and the MIC is 16.8 μg / mL, and the 4''-O-isopentenyl fusariobutenolide C can be applied to preparation of antibacterial drug precursors, and lays a material foundation for next-step biological medicine development and application of antibacterial components.

The invention provides a staphylococcus aureus drug resistance prediction method based on whole genome association analysis and machine learning, and belongs to the technical field of bioinformatics and artificial intelligence crossing. Five common antibiotics such as erythromycin, ciprofloxacin, penicillin, fusidic acid and methicillin are selected as modeling objects. Performing comparison and SNP site detection on a strain genome by using a reference genome, and constructing a variation matrix; then, a pyseer tool is adopted for GWAS analysis, and genetic loci significantly related to the drug resistance of each antibiotic are screened as modeling features; and for each antibiotic, respectively constructing an independent machine learning model, inputting the SNP features screened by the GWAS, and outputting a drug resistance / sensitivity classification label. Through cross validation and independent test set evaluation, the model has excellent accuracy and F1 score on multiple antibiotics. According to the method, drug resistance prediction can be achieved based on genome data without traditional drug sensitivity experiments, and the method has the remarkable time advantage, popularization value and scientific research significance.

The present application relates to the field of microbial technology, and discloses a strain XY-144, fermentation supernatant and application thereof.The Latin classification of the strain XY-144 is Fangia hongkongensis, the preservation unit is China General Microbiological Culture Collection Center, the preservation address is No. 1, Xibenchengli, Chaoyang District, Beijing, the preservation number is CGMCC No: 31090, and the preservation date is June 26, 2024.The fermentation supernatant prepared from the strain XY-144 can obviously inhibit the formation of methicillin-resistant Staphylococcus aureus biofilm and remove the methicillin-resistant Staphylococcus aureus biofilm, the fermentation supernatant has good thermal stability, no antibacterial activity and toxicity are found, so that the strain XY-144 and the fermentation supernatant thereof are safe and reliable in application in the food industry, which has great advantages in food application.

The application discloses an application of near-infrared controllable Fe, Zn doped tea polyphenol based carbon dot nanometer enzyme in fruit preservation, and belongs to the technical field of agricultural product preservation.The application takes tea polyphenol as a precursor, and prepares Fe, Zn doped carbon dots (Fe, Zn@GTP) nanometer enzyme with excellent antioxidant and antibacterial activity through a microwave assisted method.The Fe, Zn@GTP nanometer enzyme exhibits near-infrared light enhanced peroxidase, superoxide dismutase and catalase catalytic activity and photo-thermal performance.The Fe, Zn@GTP has antibacterial effects on escherichia coli, staphylococcus aureus, methicillin-resistant staphylococcus aureus, ampicillin-resistant escherichia coli and penicillium expansum, and the inhibition rate of the bacterial biofilm treated by the Fe, Zn@GTP is more than 90%.In the preservation experiment, the PVA / Fe, Zn@GTP film can effectively prolong the preservation period of fruits, significantly reduce the occurrence rate of fruit mold and browning, and the deterioration degree of quality indexes.

The invention relates to formononetin derivatives shown in a general formula III in the technical field of organic chemistry, and substituent groups R of the formononetin derivatives are defined in the specification. The formononetin derivative shown in the general formula III can be used for preparing antibacterial or bacteriostatic drugs, has remarkable antibacterial activity on staphylococcus aureus (S.aureus), escherichia coli (E.coli), methicillin-resistant staphylococcus aureus (MRSA) and the like, and is not resistant to drugs.

The invention discloses an aromatic polyketone compound as well as a preparation method and application thereof. The compound GaB (3) has an effect of treating infection of multiple drug-resistant bacteria. The compound is obtained by being separated from a secondary metabolite of the symbiotic Streptomyces sp.QHH-9511 of licheniformis, and the compound 2, the compound 3, the compound 4 and the compound 5 are new compounds. According to the present invention, the research results show that the GaB can effectively sterilize a variety of drug-resistant bacteria (methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, carbapenem-resistant acinetobacter baumannii, multi-drug-resistant pseudomonas aeruginosa, multi-drug-resistant salmonella, and the like); in addition, the compound has the characteristics of broad-spectrum sterilization, biofilm formation inhibition and low-frequency drug resistance, and can be combined with other antibiotics to cope with super bacteria. Mechanism research shows that GaB is combined with glucosamine-6-phosphate synthetase (GlmS) to prevent synthesis of cell walls so as to play an antibacterial role, and a plurality of constructed living body models show that the compound can effectively reduce the content of bacteria in a body and promote wound repair and has in-vivo medication safety. The research result shows that the GaB can be used as a safe and effective novel pilot natural active small molecule for resisting infection of multiple drug-resistant bacteria.

According to the screening method of the natural antibiotic-free medicine for preventing and treating methicillin-resistant staphylococcus aureus, the provided screening method can screen out the optimal medicine composition and proportion, and the screened medicine serves as an alternative scheme of antibiotic treatment; and a medicine screening and research and development foundation is laid for treating infection of methicillin-resistant staphylococcus aureus. The method for rapidly screening the natural drug monomer composition aiming at the methicillin-resistant staphylococcus aureus is provided by comprehensively applying a minimum inhibitory concentration experiment and an orthogonal method, and the method is low in cost, less in time consumption and simple to operate. The method provided by the invention verifies that the three natural drug monomers of baicalin, emodin and caffeic acid have a synergistic effect, and meanwhile, when the three drug monomers of baicalin, emodin and caffeic acid are screened according to the method provided by the invention and are combined according to the mass ratio of 2: 1: 4, the antibacterial effect on methicillin-resistant staphylococcus aureus is the best.

The application discloses a safe preservative-free sea dragon antibacterial peptide spray and a preparation method and application thereof. The spray contains sea dragon antibacterial peptide SsPle as an active ingredient and excipients. The amino acid sequence of the sea dragon antibacterial peptide SsPle is FFRSLWKGVKEGFRAGRSAYKA. The antibacterial peptide spray has the characteristics of safety, non-toxicity, non-inclusion of traditional preservatives, good stability, convenient use and the like. The antibacterial peptide has no acute oral toxicity, no mutagenicity and no chromosome damage risk, and has high biological safety. The spray is stable at 30 DEG C for 120 days, and still has a significant bacteriostatic effect on pseudomonas aeruginosa, methicillin-resistant staphylococcus aureus (MRSA) and the like. The preparation process is simple, the spray can be filled by using a quantitative sprayer, and the spray is convenient for clinical treatment, wound care and daily disinfection application. The application solves the problem of irritation of traditional antibacterial peptide sprays, is suitable for sensitive people, and has a broad market prospect.

The invention discloses an application of a bupleurum chinense extract in preparation of an antibacterial product. According to the invention, it is found for the first time that various extracts (including aqueous extracts, ethanol extracts and extraction parts of different polar solvents) of bupleurum chinense have relatively good bacteriostatic activity on streptococcus pneumoniae, methicillin-resistant staphylococcus epidermidis, micrococcus luteus and enterococcus faecium. The antibacterial spectrums and effects of different extracts are different, and the research lays a solid foundation for developing novel anti-drug-resistant bacteria drugs and natural-source antibacterial products.

The invention discloses a chain-shaped silver complex as well as a preparation method and application thereof. The invention relates to a synthesis method of a chain-like silver complex, which comprises the following steps: carrying out condensation reaction on pyridoxal and p-methylbenzenesulfonyl hydrazide to generate a pyridoxal condensed p-methylbenzenesulfonyl hydrazide ligand, reacting the ligand with silver nitrate, slowly volatilizing the reaction liquid for 3-5 days, and separating out a yellow crystal of the chain-like silver complex. The crystal is subjected to structural analysis by adopting an X-ray single crystal diffraction technology, and the result shows that the crystal is a novel chain-shaped coordination polymer. The chain-shaped silver complex shows remarkable antibacterial activity on staphylococcus aureus, pseudomonas aeruginosa, methicillin-resistant staphylococcus aureus and multi-drug-resistant pseudomonas aeruginosa, and the in-vitro antibacterial effect of the chain-shaped silver complex is superior to that of silver nitrate, a ligand and a methicillin monomer; the application potential of the compound serving as an efficient antibacterial agent in the aspect of replacing or supplementing existing anti-infection drugs is shown. The structure of a pharmaceutically acceptable compound of the chain-shaped silver complex is shown as a formula (I) in the specification.

This invention belongs to the field of veterinary drug formulation technology, specifically relating to a veterinary antimicrobial peptide sustained-release gel, its preparation method, and its application. The veterinary antimicrobial peptide sustained-release gel is made from the following materials in the indicated mass percentages: antimicrobial peptide 0.00005%~0.5%; gel matrix 0.25%~2%; excipients 2%~8%; distilled water to make up to 100%; the antimicrobial peptide is antimicrobial peptide Z(WK)2, whose amino acid sequence is shown in SEQ ID NO.1; the gel matrix includes any one or more of carboxymethyl cellulose, sodium carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, and carbomer; the excipients include any one or more of propylene glycol, glycerin, sorbitol, and polyethylene glycol. The veterinary antimicrobial peptide sustained-release gel formulation provided by this invention consists of antimicrobial peptide, gel matrix, and excipients, and exhibits significant antibacterial effect, inhibiting the proliferation of bacteria such as methicillin-resistant Staphylococcus aureus.

The scheme discloses a structural modifier of osthole at 7th position with a general formula I, wherein R 1 is phenyl or substituted phenyl; or R 1 is a hydrocarbon group with 1-5 carbon atoms; or R 1 is thiazolyl or substituted thiazolyl; and R 2 is hydrogen or a hydrocarbon group with 1-3 carbon atoms. The compound with the general formula I has strong antibacterial activity, and can be used as a medicine for resisting S.aureus, E.coli, MRSA and FREC; meanwhile, the compound can also be used in combination with other antibacterial active substances.

The application belongs to the technical field of high-performance polypropylene, and discloses an antibacterial polypropylene composite material, a preparation method thereof and a medicine bottle. The antibacterial polypropylene composite material is prepared from polypropylene, composite antibacterial particles, a lubricant and the like; wherein the polypropylene is 78-87.3%, the composite antibacterial particles are 10-18%, the lubricant is 1-2%, the antioxidant is 0.5%-2%, the toughening agent is 1%-3%, and the nucleating agent is 0.2%-0.3%. The antibacterial polypropylene composite material has high antibacterial performance and mechanical performance. In addition to having antibacterial effects on common bacteria such as Escherichia coli and Staphylococcus aureus, the antibacterial polypropylene composite material has significant antibacterial activity on drug-resistant bacteria such as vancomycin-resistant Enterococcus (VRE) and methicillin-resistant Staphylococcus aureus (MRSA), which shows the outstanding antibacterial characteristics of the antibacterial polypropylene composite material.

The invention relates to the technical field of organic chemistry, and particularly discloses an isoxazole amide derivative with a structure shown in a general formula III as well as a preparation method and application of the isoxazole amide derivative. The isoxazole amide derivative disclosed by the invention shows remarkable antibacterial activity on staphylococcus aureus, escherichia coli, methicillin-resistant staphylococcus aureus (MRSA) and fluoroquinolone-resistant escherichia coli (FREC), the activity of part of compounds is superior to that of gentamicin, and the isoxazole amide derivative has broad-spectrum antibacterial potential and can be used for preparing medicines for treating related bacterial infections.

The invention discloses two novel cytochalasin compounds with activity of inhibiting methicillin-resistant staphylococcus aureus (MRSA) and application of the cytochalasin compounds. The invention provides a compound shown as a formula (I) or a compound shown as a formula (II). The compound shown in the formula (I) is named as a compound Aizuchalasin A. The invention further discloses a preparation method of the compound. The compound shown in the formula (II) is named as a compound Aizuchlaasin B. The formula (I) is shown in the description. The compound A and the compound B of the Aizuchalasin have the activity of inhibiting methicillin-resistant staphylococcus aureus. The invention provides a lead compound for developing a new anti-MRSA medicine, and has great value for treating MRSA infection.

Cannabinoid analogs disclosed herein may exhibit antibacterial and anti-inflammatory properties. Pharmaceutical compositions comprising the cannabinoid analogs may be used to treat bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA) infections, as well as various disorders associated with chronic inflammation, such as arthritis. In some aspects, a pharmaceutical composition may be administered to an individual who has been exposed or is at risk of exposure to Bacillus anthracis or Bacillus anthracis spores.

The application belongs to the technical field of microorganisms, and discloses application of shikimic acid in preparation of antibacterial preparations for inhibiting staphyloxin synthesis. It is found that shikimic acid can inhibit synthesis of staphyloxin in methicillin-resistant Staphylococcus aureus (MRSA), reduce tolerance of the bacteria to oxidative stress, induce accumulation of intracellular active oxygen, and damage cell membrane structure and function, including reducing cell membrane order, inducing membrane depolarization, increasing membrane permeability, and leading to ATP leakage and energy metabolism disorder. A new strategy and preparation direction are provided for clinical treatment of multi-drug resistant Staphylococcus aureus infection, and the application has important theoretical value and application prospect.

The application discloses a monoterpenoid naphthoquinone compound from a sponge co-parasitic Streptomyces, and the structure is shown as formula I: the monoterpenoid naphthoquinone compound is derived from a fermentation product of Streptomyces diacarni LHW51701.The monoterpenoid naphthoquinone compound from the sponge co-parasitic Streptomyces has simple preparation method, and has the growth inhibiting effect on methicillin-resistant Staphylococcus aureus.The application provides a new compound for marine drug research, and provides a scientific basis for developing and utilizing marine antibacterial drugs in China.

The invention relates to the technical field of medical compounds, in particular to a self-sensitization anti-biofilm prodrug as well as a preparation method and application thereof. The self-sensitization anti-biofilm prodrug has a structure as shown in a formula I; wherein R1 is selected from a substituted or unsubstituted C6-C15 aryl group and a substituted or unsubstituted C6-C15 heteroaryl group, and a heteroatom in the C6-C15 heteroaryl group is selected from N; and R2 is selected from at least one of alkyl, keto and substituted or unsubstituted C6-C15 aryl. The self-sensitization anti-biofilm prodrug provided by the invention has good biofilm removal activity on methicillin-resistant staphylococcus aureus.